VIBRANT HD

Paused

ABOUT

Click here

SPONSOR

Novartis Pharmaceuticals

PARTICIPANTS

75

This is the first study of the drug branaplam in adults with HD to determine the correct dose required to lower mHTT levels in the CSF to a degree expected to be efficacious over longer periods of time.

Estimated Study Completion Date: February 17, 2025

Novartis letter to the community
"Suspending is not Ending" Article

Video introduction of Vibrant HD trial:

Ages Eligible
for Study:

25 Years to 75 Years

(Adult, Older Adult)

Sexes Eligible
for Study:

All

Accepts Healthy Volunteers:

No

Inclusion Criteria

  • Signed informed consent must be obtained prior to participation in the study.
  • Clinically diagnosed Stage 1 or 2 Huntington’s disease with a diagnostic confidence level (DCL) = 4 and a United Huntington’s Disease Rating Scale (UHDRS) Total Functional Capacity (TFC) >8 at screening.
  • Genetically confirmed Huntington’s disease, with presence of ≥40 cytosine-adenineguanine (CAG) repeats in the huntingtin gene.
  • Male and female participants between 25 to 75 years of age, inclusive, on the day of Informed Consent signature.

Exclusion Criteria

  • Prior participation in clinical trial investigating a huntingtin-lowering therapy (unless participant received only placebo).
  • Participants taking medications prohibited by the protocol.
  • Any medical history, lumbar surgery or condition that would interfere with the ability to complete the protocol specified assessments,
  • Participant has other severe, acute or chronic medical conditions including unstable psychiatric conditions, or laboratory abnormalities that in the opinion of the Investigator may increase the risk associated with study participation, or that may interfere with the interpretation of the study results.
  • Any surgical or medical condition which might put the participant at risk in case of participation in the study. The Investigator should make this determination in consideration of the participant’s medical history and/or clinical or laboratory evidence at the Screening visit:

LOCATIONS

FRANCE

  • TRIAL SITE:
    Novartis Investigative Site
  • Address: Angers Cedex 1, France, 49033

 

  • TRIAL SITE:
    Novartis Investigative Site
  • Address: Creteil, France, 94010

 

  • TRIAL SITE:
    Novartis Investigative Site
  • Address: Lille Cedex, France, 59037

HUNGARY

  • TRIAL SITE:
    Novartis Investigative Site
  • Address: Szeged, Hungary, 6725

 

  • TRIAL SITE:
    Novartis Investigative Site
  • Address: Szeged, Hungary, 6725

GERMANY

  • TRIAL SITE:
    Novartis Investigative Site
  • Address: Muenster, Germany, 48149

 

  • TRIAL SITE:
    Novartis Investigative Site
  • Address: Ulm, Germany, 89081

 

  • TRIAL SITE:
    Novartis Investigative Site
  • Address: Erlangen, Germany, 91054

SPAIN

  • TRIAL SITE:
    Novartis Investigative Site
  • Address: Barcelona, Catalunya, Spain, 08036

 

  • TRIAL SITE: Novartis Investigative Site
  • Address: Barcelona, Spain, 08041

 

  • TRIAL SITE: Novartis Investigative Site
  • Address: Madrid, Spain, 28034